KRSNAA563.45

Krsnaa Diagnostics Limited

· Pharma & Health
₹ CrorePeersSURAKSHAHEALTHXNEPHROPLUS3BBLACKBIOMcap ₹1,828 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation74.588.390.5
+ Impairment Loss / (Reversal)0.00.90.0
+ Finance Costs16.524.734.4
+ Interest Income-15.2-15.3-15.2
+ Fair Value (Gains) / Losses0.00.0-25.9
+ Share-based Payments0.94.02.2
+ Undistributed Profits of Associates0.00.00.1
+ Other Non-cash Items-7.20.00.9
+ Other — Cash Effects are Investing / Financing0.1-4.60.1
Changes in Working Capital
+ Inventories-10.76.32.8
+ Trade Receivables — Current-103.5-102.3-18.4
+ Other Financial Assets — Current-5.8-13.38.1
+ Other Financial Assets — Non-current0.42.42.7
+ Other Current Assets0.3-4.0-3.7
+ Other Non-current Assets-9.0-0.1-3.9
+ Trade Payables — Current15.719.4-43.8
+ Other Financial Liabilities — Current4.1-1.12.7
+ Other Financial Liabilities — Non-current2.40.00.0
+ Other Current Liabilities7.0-3.83.3
+ Provisions — Current0.03.13.7
+ Provisions — Non-current2.80.00.0
Cash from Operating Activities
Profit Before Tax (per I/S)70.0102.7130.4125.5
+ Total Adjustments (incl. Working Capital)-26.94.640.3
Cash from Operations (pre-tax)43.1107.3170.7
+ Income Taxes Paid18.819.927.6
Cash from Operating Activities24.387.3143.1
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)193.9126.6219.3
+ Disp of Fixed Assets0.914.93.7
+ Acq of Subsidiaries / Businesses (net)0.031.30.0
+ Loans & Advances Repaid53.725.4-188.9
+ Interest Received — Investing10.417.98.5
Cash from Investing Activities-128.9-99.6-396.0
Cash from Financing Activities
+ Proceeds from Exercise of Stock Options23.20.03.8
+ Proceeds from Debentures / Notes / Bonds0.00.0417.4
+ Proceeds from Borrowings95.758.8-92.4
+ Repayment of Borrowings5.50.00.0
+ Payment of Lease Liabilities8.215.914.0
+ Interest Paid12.421.126.6
+ Dividends Paid8.68.18.9
Cash from Financing Activities84.213.8279.3
Net Changes in Cash (pre-FX)-20.31.526.4
Net Changes in Cash-20.31.526.4
Closing Cash2.4
Reference Items
EBITDA144.2190.1211.9218.5
EBITDA Margin %23.2826.5127.4226.79
Free Cash Flow (CFO − Capex)-169.5-39.3-76.2-76.2
Free Cash Flow to Equity-16.6228.1
Free Cash Flow per Basic Share-52.27-12.12-23.48-23.48
Cash Flow to Net Income0.431.131.41
Cash Paid for Taxes18.819.927.6
Cash Paid for Interest12.421.126.6
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.